换一批
换一批伊马替尼治疗胃肠道间质瘤的继发性耐药机制
Mechanisms of secondary resistance to imatinib in gastrointestinal stromal tumors
摘要甲磺酸伊马替尼是一种高效的酪氨酸激酶抑制剂,在临床上用于进展期或手术不能切除胃肠道间质瘤(GIST)的患者.虽然取得了很好的疗效,但是容易产生耐药,耐药机制主要有原发性耐药和继发性耐药,其中继发性耐药成为近些年研究的焦点.通过对继发性耐药机制的研究,可探讨新的治疗策略.
更多相关知识
abstractsImatinib is an effective tyrosine kinase inhibitor, used in the treatment of advanced or inoperable gastrointestinal stromal tumors. Despite its efficacy, resistance is often developed among a portion of patients. Resistance to imatinib can be divided into primary and secondary resistance, with the latter becoming the focus of many recent researches. Research on the mechanisms of secondary resistance may lead to the identification of novel therapeutic strategies.
More相关知识
- 浏览255
- 被引0
- 下载68
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
